News

July 2019, AxxessBio was granted an exclusive distribution right by Amicus Therapeutics to distribute Galafold® (migalastat) in Singapore. Galafold® is the first and only oral therapy for adults with confirmed Fabry disease with an amenable GLA variant. Fabry disease is an inherited disorder that causes build- up of fats in

June 2018, AxxessBio and BioScenergy entered into an exclusive distribution agreement for BioScenergy’s Valens Metabolics range of products in selected countries in Asia.   These products are for Inborn Errors of Metabolism (IEM) which are rare genetic disorders characterised by abnormal chemical reactions in the body disrupting the normal food

February 2018, a collaboration agreement was signed between AxxessBio and myTomorrows  to create awareness on the availability of non-registered products in Asia under the Early Access Programs, e.g., Named Patient Importation, as per local regulations, and for myTomorrows’s search engine for unregistered medicinal products.   The partnership between AxxessBio and

In 2016, AxxessBio and EUSA Pharma entered into an exclusive agreement to supply Caphosol Solution and Caphosol Dispersible tablets in selected countries of Southeast Asia.   Caphosol is a mouthwash indicated for the prevention and treatment of oral mucositis due to cancer chemotherapy or radiation. It is a supersaturated solution